Tirzepatide and Retatrutide
Last Updated: September 2026A literature-based comparison of the receptor targets and in-vitro assay approaches reported for each molecule.
Reported receptor profiles
Both cited sources use engineered human-receptor systems, but the target sets and detailed assay designs differ. The table records whether each receptor forms part of the profile described for the publication's test material.
| Receptor | Tirzepatide | Retatrutide |
|---|---|---|
| GIPR | Reported target | Reported target |
| GLP-1R | Reported target | Reported target |
| GCGR | Not part of the reported dual profile | Reported target |
Shared questions, different experiments
Receptor-expression system
Both publications use engineered human-receptor cell lines. Receptor density and cell background can affect signal amplification, so values remain tied to each method.
cAMP readout
Both sources use cAMP accumulation to characterize receptor activation. Comparisons are strongest inside a single experiment with the same controls and analysis.
Additional readouts
The tirzepatide source adds β-arrestin recruitment and receptor-internalization experiments. A missing readout in another paper means it was not established by that source.
Reference ligands
Each paper selects reference ligands and normalization rules for its own questions. A percentage or potency ratio should be read with those controls.
Primary literature used here
- Willard et al. (2020), JCI Insight source — tirzepatide receptor and cell-assay characterization.
- Coskun et al. (2022), DOI source — LY3437943 receptor characterization and cAMP assay methods.